Clinical Trial Update: Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1) [Phase 3]

View source ↗

Summary

This update notes that Depemokimab is being studied as an extended-duration biologic in a Phase 3 trial (ENDURA-1) for adults with chronic obstructive pulmonary…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Depemokimab (depemokimab)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 3 | Status: RECRUITING